{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:24Z","timestamp":1792553424230,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019444","name":"Compass Therapeutics LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jad.2024.09.133","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:26:13Z","timestamp":1727454373000},"page":"381-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression \u2013 A first-in-kind open-label pilot study"],"prefix":"10.1016","volume":"369","author":[{"given":"Sara","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bostian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Conlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ostacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Suppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.09.133_bb0005","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes","author":"Aaronson","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0010","unstructured":"Aaronson, S., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H.A., in press. Single-dose psilocybin for depression with severe treatment resistance: an open-label trial. Am. J. Psychiatry."},{"key":"10.1016\/j.jad.2024.09.133_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022"},{"key":"10.1016\/j.jad.2024.09.133_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101439","article-title":"Effects of intranasal (S)-ketamine on veterans with co-morbid treatment-resistant depression and PTSD: a retrospective case series","volume":"48","author":"Artin","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2024.09.133_bb0025","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1017\/S0033291714001913","article-title":"Depression in gulf war veterans: a systematic review and meta-analysis","volume":"45","author":"Blore","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2024.09.133_bb0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0035","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.114.157859","article-title":"Risk of depressive disorder following disasters and military deployment: systematic review with meta-analysis","volume":"208","author":"Bonde","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0045","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"New England J. Med."},{"key":"10.1016\/j.jad.2024.09.133_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cpr.2015.05.001","article-title":"Dropout from individual psychotherapy for major depression: a meta-analysis of randomized clinical trials","volume":"40","author":"Cooper","year":"2015","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jad.2024.09.133_bb0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0065","first-page":"1517","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.09.133_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2015","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.jad.2024.09.133_bb0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2024.09.133_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2024.09.133_bb0085","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2024.09.133_bb0090","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.amepre.2022.05.014","article-title":"Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap","volume":"63","author":"Goodwin","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.jad.2024.09.133_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jad.2024.09.133_bb0100","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0110","article-title":"Psychological therapies for treatment-resistant depression in adults","volume":"5","author":"Ijaz","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2024.09.133_bb0115","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0120","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1080\/14656566.2023.2281582","article-title":"Psychedelics for treatment resistant depression: are they game changers?","volume":"24","author":"Kalfas","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jad.2024.09.133_bb0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s10615-019-00703-5","article-title":"Prevalence of adverse childhood experiences among veterans","volume":"47","author":"Laird","year":"2019","journal-title":"Clin. Soc. Work. J."},{"key":"10.1016\/j.jad.2024.09.133_bb0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1521\/pdps.2014.42.3.459","article-title":"The mental health needs of military service members and veterans","volume":"42","author":"Lazar","year":"2014","journal-title":"Psychodyn. Psych."},{"key":"10.1016\/j.jad.2024.09.133_bb0135","series-title":"Major Depressive Disorder","author":"McIntyre","year":"2019"},{"key":"10.1016\/j.jad.2024.09.133_bb0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0028-3908(90)90001-8","article-title":"Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes","volume":"29","author":"McKenna","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2024.09.133_bb0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.09.133_bb0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0160","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0170","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0175","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023"},{"key":"10.1016\/j.jad.2024.09.133_bb0180","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.09.133_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0195","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/02698811231190858","article-title":"Psilocybin history, action and reaction: a narrative clinical review","volume":"37","author":"Sharma","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0205","series-title":"Handbook of Psychiatric Measures","first-page":"113","article-title":"Sheehan disability scale","author":"Sheehan","year":"2000"},{"key":"10.1016\/j.jad.2024.09.133_bb0210","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59 Suppl 20","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0215","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.133_bb0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1037\/a0028226","article-title":"Premature discontinuation in adult psychotherapy: a meta-analysis","volume":"80","author":"Swift","year":"2012","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.jad.2024.09.133_bb0225","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/03007995.2021.1918073","article-title":"Economic burden of treatment-resistant depression among veterans in the United States","volume":"37","author":"Szukis","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2024.09.133_bb0230","article-title":"Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research","volume":"12","author":"Tai","year":"2021","journal-title":"Front. Psych."},{"issue":"Suppl. 13","key":"10.1016\/j.jad.2024.09.133_bb0235","first-page":"18","article-title":"Evaluating antidepressant therapies: remission as the optimal outcome","volume":"64","author":"Thase","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0245","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.2105\/AJPH.2015.302836","article-title":"Prevalence, comorbidity, and prognosis of mental health among US veterans","volume":"105","author":"Trivedi","year":"2015","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.jad.2024.09.133_bb0250","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2024.09.133_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02687038.2018.1454884","article-title":"Statistical analysis in small-N designs: using linear mixed-effects modeling for evaluating intervention effectiveness","volume":"33","author":"Wiley","year":"2019","journal-title":"Aphasiology"},{"key":"10.1016\/j.jad.2024.09.133_bb0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery-\u00c5sberg Depression Rating Scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.133_bb0265","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jad.2022.03.058","article-title":"Characteristics and current standard of care among veterans with major depressive disorder in the United States: a real-world data analysis","volume":"307","author":"Zhao","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.09.133_bb0270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jad.2021.04.033","article-title":"Comorbid mental disorders, depression symptom severity, and role impairment among veterans initiating depression treatment through the veterans health administration","volume":"290","author":"Ziobrowski","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.09.133_bb0275","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jad.2016.07.023","article-title":"Characteristics of U.S. veteran patients with major depressive disorder who require \u201cnext-step\u201d treatments: a VAST-D report","volume":"206","author":"Zisook","year":"2016","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724016227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724016227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T09:12:48Z","timestamp":1733476368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724016227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"alternative-id":["S0165032724016227"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.09.133","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression \u2013 A first-in-kind open-label pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.09.133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}